Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PpPfs25
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**PpPfs25** is a Pichia-expressed recombinant form of the *Plasmodium falciparum* sexual-stage surface antigen Pfs25. It is a protein-subunit transmission-blocking malaria vaccine antigen intended to elicit anti-Pfs25 antibodies; when a mosquito ingests these antibodies in a blood meal, they inhibit parasite development in the mosquito and thereby reduce onward transmission. PpPfs25 was evaluated by NIAID in a Phase 1 study as the adjuvanted formulation PpPfs25/ISA51. The trial showed induction of Pfs25-specific, transmission-blocking antibodies, but the ISA51 formulation caused substantial local reactogenicity and systemic adverse events, limiting further development of that formulation. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403551/))
- Other names
- Pichia-expressed recombinant Pfs25Pichia-produced Pfs25PpPfs25PpPfs-25PpPfs 25
02
Targets
Pfs25
Beyond the preview
Go deeper on PpPfs25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PpPfs25.